Peripherally expressed neprilysin reduces brain amyloid burden

A novel approach for treating Alzheimer's disease

Hanjun Guan, Yinxing Liu, Abigail Daily, Sara Police, Myung Hee Kim, Salvatore Oddo, Frank M. LaFerla, James R. Pauly, M. Paul Murphy, Louis B. Hersh

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

A number of therapeutic strategies for treating Alzheimer's disease have focused on reducing amyloid burden in the brain. Among these approaches, the expression of amyloid β peptide (Aβ)-degrading enzymes in the brain has been shown to be effective but to date not practical for treating patients. We report here a novel strategy for lowering amyloid burden in the brain by peripherally expressing the Aβ-degrading enzyme neprilysin on leukocytes in the 3×Tg-AD mouse model of Alzheimer's disease. Through transplantation of lentivirus-transduced bone marrow cells, the Aβ-degrading protease neprilysin was expressed on the surface of leukocytes. This peripheral neprilysin reduced soluble brain Aβ peptide levels by ∼30% and lowered the accumulation of amyloid β peptides by 50-60% when transplantation was performed at both young and early adult age. In addition, peripheral neprilysin expression reduced amyloid-dependent performance deficits as measured by the Morris water maze. Unlike other methods designed to lower Aβ levels in blood, which cause a net increase in peptide, neprilysin expression results in the catabolism of Aβ to small, innocuous peptide fragments. These findings demonstrate that peripherally expressed neprilysin, and likely other Aβ-degrading enzymes, has the potential to be utilized as a therapeutic approach to prevent and treat Alzheimer's disease and suggest that this approach should be explored further.

Original languageEnglish (US)
Pages (from-to)1462-1473
Number of pages12
JournalJournal of Neuroscience Research
Volume87
Issue number6
DOIs
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Neprilysin
Amyloid
Alzheimer Disease
Brain
Peptides
Leukocytes
Enzymes
Transplantation
Lentivirus
Peptide Fragments
Bone Marrow Cells
Young Adult
Peptide Hydrolases
Water
Therapeutics

Keywords

  • Amyloid clearance
  • Gene therapy
  • Peptidases

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Peripherally expressed neprilysin reduces brain amyloid burden : A novel approach for treating Alzheimer's disease. / Guan, Hanjun; Liu, Yinxing; Daily, Abigail; Police, Sara; Kim, Myung Hee; Oddo, Salvatore; LaFerla, Frank M.; Pauly, James R.; Murphy, M. Paul; Hersh, Louis B.

In: Journal of Neuroscience Research, Vol. 87, No. 6, 01.05.2009, p. 1462-1473.

Research output: Contribution to journalArticle

Guan, H, Liu, Y, Daily, A, Police, S, Kim, MH, Oddo, S, LaFerla, FM, Pauly, JR, Murphy, MP & Hersh, LB 2009, 'Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease', Journal of Neuroscience Research, vol. 87, no. 6, pp. 1462-1473. https://doi.org/10.1002/jnr.21944
Guan, Hanjun ; Liu, Yinxing ; Daily, Abigail ; Police, Sara ; Kim, Myung Hee ; Oddo, Salvatore ; LaFerla, Frank M. ; Pauly, James R. ; Murphy, M. Paul ; Hersh, Louis B. / Peripherally expressed neprilysin reduces brain amyloid burden : A novel approach for treating Alzheimer's disease. In: Journal of Neuroscience Research. 2009 ; Vol. 87, No. 6. pp. 1462-1473.
@article{f209f132c82f4f4f96c6d87de1882bf6,
title = "Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease",
abstract = "A number of therapeutic strategies for treating Alzheimer's disease have focused on reducing amyloid burden in the brain. Among these approaches, the expression of amyloid β peptide (Aβ)-degrading enzymes in the brain has been shown to be effective but to date not practical for treating patients. We report here a novel strategy for lowering amyloid burden in the brain by peripherally expressing the Aβ-degrading enzyme neprilysin on leukocytes in the 3×Tg-AD mouse model of Alzheimer's disease. Through transplantation of lentivirus-transduced bone marrow cells, the Aβ-degrading protease neprilysin was expressed on the surface of leukocytes. This peripheral neprilysin reduced soluble brain Aβ peptide levels by ∼30{\%} and lowered the accumulation of amyloid β peptides by 50-60{\%} when transplantation was performed at both young and early adult age. In addition, peripheral neprilysin expression reduced amyloid-dependent performance deficits as measured by the Morris water maze. Unlike other methods designed to lower Aβ levels in blood, which cause a net increase in peptide, neprilysin expression results in the catabolism of Aβ to small, innocuous peptide fragments. These findings demonstrate that peripherally expressed neprilysin, and likely other Aβ-degrading enzymes, has the potential to be utilized as a therapeutic approach to prevent and treat Alzheimer's disease and suggest that this approach should be explored further.",
keywords = "Amyloid clearance, Gene therapy, Peptidases",
author = "Hanjun Guan and Yinxing Liu and Abigail Daily and Sara Police and Kim, {Myung Hee} and Salvatore Oddo and LaFerla, {Frank M.} and Pauly, {James R.} and Murphy, {M. Paul} and Hersh, {Louis B.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1002/jnr.21944",
language = "English (US)",
volume = "87",
pages = "1462--1473",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Peripherally expressed neprilysin reduces brain amyloid burden

T2 - A novel approach for treating Alzheimer's disease

AU - Guan, Hanjun

AU - Liu, Yinxing

AU - Daily, Abigail

AU - Police, Sara

AU - Kim, Myung Hee

AU - Oddo, Salvatore

AU - LaFerla, Frank M.

AU - Pauly, James R.

AU - Murphy, M. Paul

AU - Hersh, Louis B.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - A number of therapeutic strategies for treating Alzheimer's disease have focused on reducing amyloid burden in the brain. Among these approaches, the expression of amyloid β peptide (Aβ)-degrading enzymes in the brain has been shown to be effective but to date not practical for treating patients. We report here a novel strategy for lowering amyloid burden in the brain by peripherally expressing the Aβ-degrading enzyme neprilysin on leukocytes in the 3×Tg-AD mouse model of Alzheimer's disease. Through transplantation of lentivirus-transduced bone marrow cells, the Aβ-degrading protease neprilysin was expressed on the surface of leukocytes. This peripheral neprilysin reduced soluble brain Aβ peptide levels by ∼30% and lowered the accumulation of amyloid β peptides by 50-60% when transplantation was performed at both young and early adult age. In addition, peripheral neprilysin expression reduced amyloid-dependent performance deficits as measured by the Morris water maze. Unlike other methods designed to lower Aβ levels in blood, which cause a net increase in peptide, neprilysin expression results in the catabolism of Aβ to small, innocuous peptide fragments. These findings demonstrate that peripherally expressed neprilysin, and likely other Aβ-degrading enzymes, has the potential to be utilized as a therapeutic approach to prevent and treat Alzheimer's disease and suggest that this approach should be explored further.

AB - A number of therapeutic strategies for treating Alzheimer's disease have focused on reducing amyloid burden in the brain. Among these approaches, the expression of amyloid β peptide (Aβ)-degrading enzymes in the brain has been shown to be effective but to date not practical for treating patients. We report here a novel strategy for lowering amyloid burden in the brain by peripherally expressing the Aβ-degrading enzyme neprilysin on leukocytes in the 3×Tg-AD mouse model of Alzheimer's disease. Through transplantation of lentivirus-transduced bone marrow cells, the Aβ-degrading protease neprilysin was expressed on the surface of leukocytes. This peripheral neprilysin reduced soluble brain Aβ peptide levels by ∼30% and lowered the accumulation of amyloid β peptides by 50-60% when transplantation was performed at both young and early adult age. In addition, peripheral neprilysin expression reduced amyloid-dependent performance deficits as measured by the Morris water maze. Unlike other methods designed to lower Aβ levels in blood, which cause a net increase in peptide, neprilysin expression results in the catabolism of Aβ to small, innocuous peptide fragments. These findings demonstrate that peripherally expressed neprilysin, and likely other Aβ-degrading enzymes, has the potential to be utilized as a therapeutic approach to prevent and treat Alzheimer's disease and suggest that this approach should be explored further.

KW - Amyloid clearance

KW - Gene therapy

KW - Peptidases

UR - http://www.scopus.com/inward/record.url?scp=65549114145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549114145&partnerID=8YFLogxK

U2 - 10.1002/jnr.21944

DO - 10.1002/jnr.21944

M3 - Article

VL - 87

SP - 1462

EP - 1473

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 6

ER -